1 | Knapp K, Lenz W, Nowack E: Multiple congenital abnormalities. Lancet 2:725, 1962 |
2 | Wilson JG: Environment and Birth Defects. New York, Academic Press, 1973 |
3 | Wilson JG: Differentiation and the reaction of rat embryos to radiation. J Cell Comp Physiol 43:Suppl 1:11, 1954 |
4 | Fraser FC, Fainstat TD: Production of congenital defects in the offspring of pregnant mice treated with cortisone. Pediatrics 8:527, 1951 |
5 | Jacobson BD: Hazards of norethindrone therapy during pregnancy. Am J Obstet Gynecol 84:962, 1962 |
6 | Phelan MC, Pollock JM, Nance WE: Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins. N Engl J Med 307:99, 1982 |
7 | Vessell ES: Genetic and environmental factors affecting drug metabolism in man. Proceedings of the 4th International Congress on Human Genetics Paris, International Congress Series 250, 391, 1972 |
8 | Peer LA, Bryan WH, Strean LP et al: Induction of cleft palate in mice by cortisone and its reduction by vitamins. J Int Coll Surg 30:249, 1958 |
9 | Kimmel CA, Wilson JG, Schumacher HJ: Studies on metabolism and identification of the causative agent in aspirin teratogenesis in the rat. Teratology 4:15, 1971 |
10 | Kalter M: Interplay of intrinsic and extrinsic factors. In: Wilson JG, Warkany J (eds): Teratology: Principles and Techniques, Chicago. University of Illinois Press, 57, 1965 |
11 | Saxen L: Defective regulatory mechanisms in teratogenesis. Int J Gynaecol Obstet 8:798, 1970 |
12 | Simpson JL: Relationship between congenital anomalies and contraception. Adv Contracep 1:3, 1985 |
13 | Sever LE, Mortenson ML: Teratology and the epidemiology of birth defects. In: Gabbe SG, Niebyl JR, Simpson JL (eds): Obstetrics: Normal and Problem Pregnancies. New York, Churchill-Livingstone, 185–214, 1996 |
14 | Wilson JG, Fraser FC (eds): Handbook of Teratology. New York, Plenum, 1979 |
15 | Teratology Society Public Affairs Committee. FDA Classification of drugs for teratogenic risk Teratol 49:446, 1994 |
16 | Doering PL, Boothby LA, Cheok M: Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks. Am J Obstet Gynecol 187:333, 2002 |
17 | Lammer EJ, Chen DT, Hoar RM et al: Retinoic acid embryopathy. N Engl J Med 313:837, 1985 |
18 | Adams J: High incidence of intellectual deficits in 5-year-old children exposed to isotretinoin “in utero”. Teratology 41:614, 1990 |
19 | Dai WS, Hsu M-A, Itri L: Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol 125:362, 1989 |
20 | Jick SS, Terris BZ, Jick H: First trimester topical tretinoin and congenital disorders. Lancet 341:1181, 1993 |
21 | Geiger JM, Baudin M, Saurat JH: Teratogenic risk with etritinate and acitretin treatment. Dermatology 189:109, 1994 |
22 | Rothman KJ, Moore LL, Singer MR et al: Teratogenicity of high vitamin A intake. N Engl J Med 333:1369, 1995 |
23 | Mills JL, Simpson JL, Cunningham GC et al: Vitamin A and birth defects. Am J Obstet Gynecol 177:31, 1997 |
24 | Kozlowski RD, Steinbrunner JV, MacKenzie AH et al: Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 88:589, 1990 |
25 | Armenti VT, Ahlswede BA, Ahlswede JR et al: National transplantation pregnancy registry: Analysis of outcome/risks of 394 pregnancies in kidney transplant recipients. Transplant Proc 26:2535, 1994 |
26 | Polifka JE, Friedman JM: Teratogen update: Azathioprine and 6-mercaptopurine. Teratol 65:240, 2002 |
27 | Armenti VT, Moritz MJ, Davison JM: Drug safety issues in pregnancy following transplantation and immunosuppression: Effects and outcomes. Drug Saf 19:219, 1998 |
28 | Takahashi N, Nishida H, Hoshi J: Severe B cell depletion in newborns from renal transplant mothers taking immunosuppressive agents. Transplantation 57:1617, 1994 |
29 | Briggs GC, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 339, 2002 |
30 | Wolfe MS, Cordero JF: Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J 290:1466, 1985 |
31 | Hart CW, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol 80:407, 1964 |
32 | Levy M, Buskila D, Gladman DD et al: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 8:174, 1991 |
33 | Zemlickis D, Lishner M, Degendorfer P et al: Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152:573, 1992 |
34 | Robert E, Guibaud P: Maternal valproic acid and congenital neural tube defects. Lancet 2:937, 1982 |
35 | Rosa FW: Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 324:674, 1991 |
36 | Holmes LB, Harvey EA, Coull BA et al: The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132, 2001 |
37 | Dansky LV, Rosenblatt DS, Andermann E: Mechanisms of teratogenesis: Folic acid and antiepileptic therapy. Neurology 42:32, 1992 |
38 | Centers for Disease Control: Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep 41:1, 1992 |
39 | Biale Y, Lewenthal H: Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 18:211, 1984 |
40 | Hanson JW, Smith DW: The fetal hydantoin syndrome. J Pediatr 87:285, 1975 |
41 | Gaily E, Granstrom M-L, Hiilesmaa V et al: Minor anomalies in offspring of epileptic mothers. J Pediatr 112:520, 1988 |
42 | Jones KL, Lacro RV, Johnson KA et al: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320:1661, 1989 |
43 | Strickler SM, Miller MA, Andermann E et al: Genetic predisposition to phenytoin-induced birth defects. Lancet 2:746, 1985 |
44 | Buehler BA, Delimont D, VanWaes M et al: Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 322:1567, 1990 |
45 | Van der Pol MC, Hadders-Algra M, Huisjes JH et al: Antiepileptic medication in pregnancy: Late effects on the children's central nervous system development. Am J Obstet Gynecol 164:121, 1991 |
46 | Scolnik D, Nulman I, Rovet J et al: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:767, 1994 |
47 | Reinisch JM, Sanders SA, Mortensen EL et al: In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 274:1518, 1995 |
48 | Reiff-Eldridge R, Heffner CR, Ephross SA et al: Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am J Obstet Gynecol 182:159, 2000 |
49 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 766–769, 2002 |
50 | Tennis P, Eldridge RR: International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine Epilepsia 43:1161, 2002 |
51 | Callaghan N, Garrett A, Goggin T: Withdrawal of anticonvulsant drugs in patients free of seizures for two years. N Engl J Med 318:942, 1988 |
52 | Deblay MF, Vert P, Andre M et al: Transplacental vitamin K prevents haemorrhagic disease of infant of epileptic mother. Lancet 1:1247, 1982 |
53 | Haddow JE, Palomaki GE, Allan WC et al: Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 341:549, 1999 |
54 | Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122, 1980 |
55 | Sbarouni E, Oakley CM: Outcome of pregnancy in women with valve prostheses. Br Heart J 71:196, 1994 |
56 | deSwiet M, Ward PD, Fidler J et al: Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 90:1129, 1983 |
57 | Barbour LA, Kick SD, Steiner JF et al: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862, 1994 |
58 | Dahlman TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265, 1993 |
59 | Nelson-Piercy C, Letsky EA, deSwiet M: Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 176:1062, 1997 |
60 | Casele HL, Laifer SA, Woelkers DA et al: Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 181:1113, 1999 |
61 | Ginsberg JS, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 114:524S, 1998 |
62 | Chan WS, Ray JG: Low molecular weight heparin use during pregnancy: Issues of safety and practicality. Obstet Gynecol Surv 54:649, 1999 |
63 | Tengborn L, Bergqvist D, Matzsch T et al: Recurrent thromboembolism in pregnancy and puerperium: Is there a need for thromboprophylaxis. Am J Obstet Gynecol 160:90, 1989 |
64 | Lao TT, deSwiet M, Letsky E et al: Prophylaxis of thromboembolism in pregnancy: An alternative. Br J Obstet Gynaecol 92:202, 1985 |
65 | Meschengieser SS, Fondevila CG, Santarelli MT et al: Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 82:23, 1999 |
66 | Iturbe-Alessio I, del Carmen Fonseca M, Mutchinik O et al: Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315:1390, 1986 |
67 | Mujtaba Q, Burrow GN: Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol 46:282, 1975 |
68 | Wing DA, Millar LK, Koonings PP et al: A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 170:90, 1994 |
69 | Burrow GN: Thyroid diseases. In: Burrow GN, Ferris TF (eds): Medical Complications During Pregnancy. Philadelphia, WB Saunders, p 229, 1988 |
70 | Mandel SJ, Larsen PR, Seely EW et al: Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 323:91, 1990 |
71 | l'Allemand D, Gruters A, Heidemann P et al: Iodine-induced alterations of thyroid function in newborn infants after prenatal and perinatal exposure to povidone iodine. J Pediatr 102:935, 1983 |
72 | Czeizel A: Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. Reprod Toxicol 3:183, 1988 |
73 | Laegreid L, Olegard R, Wahlstrom J et al: Abnormalities in children exposed to benzodiazepines in utero. Lancet 1:108, 1987 |
74 | Bergman V, Rosa F, Baum C et al: Effects of exposure to benzodiazepine during fetal life. Lancet 340:694, 1992 |
75 | Linden S, Rich CL: The use of lithium during pregnancy and lactation. J Clin Psychiatry 44:358, 1983 |
76 | Weinstein MR, Goldfield MD: Cardiovascular malformations with lithium use during pregnancy. Am J Psychiatry 132:529, 1975 |
77 | Zalzstein E, Koren G, Einarson T et al: A case-control study on the association between first trimest exposure to lithium and Ebstein's anomaly. Am J Cardiol 65:817, 1990 |
78 | Jacobson SJ, Jones K, Johnson K et al: Prospective multi-centre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339:530, 1992 |
79 | Krause S, Ebbesen F, Lange AP: Polyhydramnios with maternal lithium treatment. Obstet Gynecol 75:504, 1990 |
80 | Ang MS, Thorp JA, Parisi VM: Maternal lithium therapy and polyhydramnios. Obstet Gynecol 76:517, 1990 |
81 | Cohen LS, Friedman MJ, Jefferson JW: A reevaluation of risk of in utero exposure to lithium. JAMA 271:146, 1994 |
82 | Cohen LS, Altshuler LL, Harlow BL et al: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499, 2006 |
83 | Briggs GC, Freeman RK, Jaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 693, 2002 |
84 | Briggs GC, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 60, 2002 |
85 | Pastuszak A, Schick-Boschetto B, Zuber C et al: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269:2446, 1993 |
86 | Goldstein DJ, Corbin LA, Sundell KL: Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 89:713, 1997 |
87 | Nulman I, Rovert J, Stewart DE et al: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258, 1997 |
88 | Chambers CD, Johnson KA, Dick LM et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010, 1996 |
89 | Kulin NA, Pastuszak A, Sage SR et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. JAMA 279:609, 1998 |
90 | Nulman I, Rovet J, Stewart DE et al: Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am J Psych 159:1889, 2002 |
91 | Hendrick V, Smith LM, Suri R et al: Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188:812, 2003 |
92 | Louik C, Lin AE, Werler MM et al: First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675, 2007 |
93 | Alwan S, Reefhuis J, Rasmussen SA, et al: Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684, 2007 |
94 | Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579, 2006 |
95 | ACOG Committee on Practice Bulletins No. 92, American College of Obstetricians and Gynecologists: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111:1001, 2008 |
96 | Sahakian V, Rouse D, Sipes S et al: Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized double-blind, placebo-controlled study. Obstet Gynecol 78:33, 1991 |
97 | Vutyavanich T, Wongtra-Rjan S, Ruangsri R: Pyridoxine for nausea and vomiting of pregnancy: A randomized double-blind placebo-controlled trial. Am J Obstet Gynecol 173:881, 1995 |
98 | Diggory PLC, Tomkinson JS: Nausea and vomiting in pregnancy: A trial of meclozine dihydrochloride with and without pyridoxine. Lancet 2:370, 1962 |
99 | Heinonen OP, Slone S, Shapiro S: Birth Defects and Drugs in Pregnancy. Littleton, MA, Publishing Sciences Group, 1977 |
100 | Milkovich L, Van Den Berg BJ: An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 125:244, 1976 |
101 | Cartwright EW: Dramamine in nausea and vomiting of pregnancy. West J Surg Obstet Gynecol 59:216, 1951 |
102 | Sorensen HT, Nielsen GL, Christensen K et al: Birth outcomes following maternal use of metoclopramide. Br J Clin Pharmacol 49:264, 2000 |
103 | Sullivan CA, Johnson CA, Roach H et al: A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 174:2565, 1996 |
104 | Safari HR, Fassett MJ, Souter IC et al: The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: A randomized, double-blind, controlled study. Am J Obstet Gynecol 179:921, 1998 |
105 | Park-Wyllie L, Mazzotta P, Pastuszak A et al: Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385, 2000 |
106 | Carmichael SL, Shaw GM: Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 86:242, 1999 |
107 | Vutyavanich T, Kraisarin T, Ruangsri R: Ginger for nausea and vomiting in pregnancy: Randomized, double-masked, placebo-controlled trial. Obstet Gynecol 97:577, 2001 |
108 | Fischer-Rasmussen W, Kjaer SK, Dahl C et al: Ginger treatment of hyperemesis gravidarum. Europ J Obstet Gynecol Reprod Biol 138:19, 1990 |
109 | Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C et al: Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150:476, 1999 |
110 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1321, 2002 |
111 | Pastuszak A, Schick B, D'Alimonte D et al: The safety of astemizole in pregnancy. J Allergy Clin Immunol 98:748, 1996 |
112 | Zierler S, Purohit D: Prenatal antihistamine exposure and retrolental fibroplasia. Am J Epidemiol 123:192, 1986 |
113 | Werler MM, Mitchell AA, Shapiro S: First trimester maternal medication use in relation to gastroschisis. Teratology 45:361, 1992 |
114 | Werler MM, Mitchell AA, Shapiro S: The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 321:1639, 1989 |
115 | Kozer E, Nikfar S, Costei A et al: Aspirin consumption during the first trimester of pregnancy and congenital anomalies: A meta-analysis. Am J Obstet Gynecol 187:1623, 2002 |
116 | Collins E, Turner G: Salicylates and pregnancy. Lancet 2:1494, 1973 |
117 | Stuart JJ, Gross SJ, Elrad H et al: Effects of acetylsalicylic acid ingestion on maternal and neonatal hemostasis. N Engl J Med 307:909, 1982 |
118 | Areilla RA, Thilenius OB, Ranniger K: Congestive heart failure from suspected ductal closure in utero. J Pediatr 75:74, 1969 |
119 | Cowchock FS, Reece EA, Balaban D et al: Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 166:1318, 1992 |
120 | Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 100:408, 2002 |
121 | Thulstrup AM, Sorensen HT, Nielsen GL et al: Fetal growth and adverse birth outcomes in women receiving prescriptions for acetaminophen during pregnancy. Am J Perinatol 16:321, 1999 |
122 | Waltman T, Tricomi V, Tavakoli FM: Effect of aspirin on bleeding time during elective abortion. Obstet Gynecol 48:108, 1976 |
123 | Rayburn W, Shukla U, Stetson P et al: Acetaminophen pharmacokinetics: Comparison between pregnant and nonpregnant women. Obstet Gynecol 155:1353, 1986 |
124 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 685–687, 2002 |
125 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 171–172, 2002 |
126 | Tyson HK: Neonatal withdrawal symptoms associated with maternal use of propoxyphene hydrochloride (Darvon). J Pediatr 85:684, 1974 |
127 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1301, 2002 |
128 | Czeizel AE, Rockenbauer M, Sorensen HT et al: Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: A population-based, case-control study. Am J Obstet Gynecol 184:1289, 2001 |
129 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 1291–1295, 2002 |
130 | Jarnerot G, Into-Malmberg MB, Esbjorner E: Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 16:693, 1981 |
131 | Ochoa AG: Trimethoprim and sulfamethoxazole in pregnancy. JAMA 217:1244, 1971 |
132 | Brumfitt W, Pursell R: Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br Med J 2:673, 1972 |
133 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. 6th ed. Baltimore, Williams & Wilkins, p 1394, 2002 |
134 | Czeizel A: A case-control analysis of the teratogenic effects of co-trimoxazole. Reprod Toxicol 4:305, 1990 |
135 | Hernandez-Diaz S, Werler MM, Walker AM et al: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343:1608, 2002 |
136 | Hailey FJ, Fort H, Williams JR et al: Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: A retrospective analysis. J Int Med Res 11:364, 1983 |
137 | Lenke RR, VanDorsten JP, Schifrin BS: Pyelonephritis in pregnancy: A prospective randomized trial to prevent recurrent disease evaluating suppressive therapy with nitrofurantoin and close surveillance. Am J Obstet Gynecol 146:953, 1983 |
138 | Cohlan SQU, Bevelander G, Tiamsic T: Growth inhibition of prematures receiving tetracycline. Am J Dis Child 105:453, 1963 |
139 | Aselton P, Jick H, Mulnsky A et al: First-trimester drug use and congenital disorders. Obstet Gynecol 65:451, 1985 |
140 | Czeizel AE, Rockenbauer M: Teratogenic study of doxycyline. Obstet Gynecol 89:524, 1997 |
141 | Robinson GC, Cambon KG: Hearing loss in infants of tuberculous mothers treated with streptomycin during pregnancy. N Engl J Med 271:949, 1964 |
142 | Nishimura H, Tanimura T: Clinical Aspects of the Teratogenicity of Drugs. Amsterdam, Excerpta Medica, 1976 |
143 | L'Hommedieu CS, Nicholas D, Armes DA et al: Potentiation of magnesium ulfate-induced neuromuscular weakness by gentamicin, tobramycin, and amikacin. J Pediatr 102:629, 1983 |
144 | Marynowski A, Sianozecka E: Comparison of the incidence of congenital malformations in neonates from healthy mothers and from patients treated because of tuberculosis. Ginekol Pol 43:713, 1972 |
145 | Zaske DE, Cipolle RJ, Strate RG et al: Rapid gentamicin elimination in obstetric patients. Obstet Gynecol 56:559, 1980 |
146 | Mitra AG, Whitten MK, Laurent SL et al: A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection. Am J Obstet Gynecol 177:786, 1997 |
147 | American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149:1359, 1994 |
148 | Philipson A, Sabath LD, Charles D: Transplacental passage of erythromycin and clindamycin. N Engl J Med 288:1219, 1973 |
149 | South MA, Short DH, Knox JM: Failure of erythromycin estolate therapy in in utero syphilis. JAMA 190:70, 1964 |
150 | Einarson A, Phillips E, Mawji F et al: A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 15:523, 1998 |
151 | Briggs GC, Freeman RK, Jaffe SJ: Drugs in Pregnancy and Lactation. 6th ed.. Baltimore, Williams & Wilkins, 286, 2002 |
152 | Berkovitch M, Pastuszak A, Gazarian M et al: Safety of the new quinolones in pregnancy. Obstet Gynecol 84:535, 1994 |
153 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and lactation. 6th ed. Baltimore, Williams & Wilkins, p 270, 2002 |
154 | Piper JM, Mitchel EF, Ray WA: Prenatal use of metronidazole and birth defects: No association. Obstet Gynecol 82:348, 1993 |
155 | Burtin P, Taddio A, Ariburnu O et al: Safety of metronidazole in pregnancy: A meta-analysis. Am J Obstet Gynecol 172:525, 1995 |
156 | Culnane M, Fowler MG, Lee SS et al: Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281:151, 1999 |
157 | McGowan JP, Crane M, Wiznia AA et al: Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 94:641, 1999 |
158 | Watts DH: Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 346:1879, 2002 |
159 | Rosa FW, Baum C, Shaw M: Pregnancy outcomes after first trimester vaginitis drug therapy. Obstet Gynecol 69:751, 1987 |
160 | Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and lactation. 6th ed. Baltimore, Williams & Wilkins, p 300, 2002 |
161 | Pursley TJ, Blomquist IK, Abraham J et al: Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 22:336, 1996 |
162 | Jick SS: Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy 19:221, 1999 |
163 | Mastroiacovo P, Mazzone T, Botto LD et al: Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obstet Gynecol 175:1645, 1996 |
164 | Main EK, Main DM, Gabbe SG: Chronic oral terbutaline therapy is associated with maternal glucose intolerance. Obstet Gynecol 157:644, 1987 |
165 | Weiner CP, Landas S, Persoon TJ: Digoxin-like immunoreactive substance in fetuses with and without cardiac pathology. Am J Obstet Gynecol 157:368, 1987 |
166 | Weiner CP, Thompson MIB: Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. Am J Obstet Gynecol 158:570, 1988 |
167 | Pruyn SC, Phelan JP, Buchanan GC: Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol 135:485, 1979 |
168 | Redmond GP: Propranolol and fetal growth retardation. Semin Perinatol 6:142, 1982 |
169 | Magee LA, Bull SB, Kren G et al: The generalizability of trial data; a comparison of β-blocker trial participants with a prospective cohort of women taking β-blockers in pregnancy. Europ J Obstet Gynecol Reprod Biol 94:205, 2001 |
170 | Lydakis C, Lip GYH, Beevers M et al: Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertension 12:541, 1999 |
171 | Easterling TR, Carr DB, Brateng D et al: Treatment of hypertension in pregnancy: Effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 98:427, 2001 |
172 | Burrows RF, Burrows EA: Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZJ Obstet Gynecol 38:3:306, 1998 |
173 | Hanssens M, Keirse MJNC, Vankelecom F et al: Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 78:128, 1991 |
174 | Piper JM, Ray WA, Rosa FW: Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol 80:429, 1992 |
175 | Asch RH, Greenblatt RB: Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. J Reprod Med 17:175, 1976 |
176 | Riuz-Velasco V, Tolis G: Pregnancy in hyperprolactinemic women. Fertil Steril 41:793, 1984 |
177 | Wiseman RA, Dodds-Smith IC: Cardiovascular birth defects and antenatal exposure to female sex hormones: A reevaluation of some base data. Teratology 30:359, 1984 |
178 | Katz Z, Lancet M, Skornik J et al: Teratogenicity of progestagens given during the first trimester of pregnancy. Obstet Gynecol 65:775, 1985 |
179 | Raman-Wilms L, Tseng AL, Wighardt S et al: Fetal genital effects of first-trimester sex hormone exposure: A meta-analysis. Obstet Gynecol 85:141, 1995 |
180 | Wilkins L: Masculinization of female fetus due to use of orally given progestins. JAMA 172:1028, 1960 |
181 | Duck SC, Katayama KP: Danazol may cause female pseudohermaphroditism. Fertil Steril 35:230, 1981 |
182 | Shapiro S, Slone D, Heinonen OP et al: Birth defects and vaginal spermicides. JAMA 247:2381, 1982 |
183 | Mills JL, Reed GF, Nugent RP et al: Are there adverse effects of periconceptional spermicide use. Fertil Steril 43:442, 1985 |
184 | Linn S, Schoenbaum SC, Monson RR et al: Lack of association between contraceptive usage and congenital malformations in offspring. Am J Obstet Gynecol 147:923, 1983 |
185 | Shah NR, Bracken MB: A systematic review and meta-analysis of prospective studies on the association between interval cigarette smoking and preterm delivery. Am J Obstet Gynecol 182:465, 2000 |
186 | Alberman E, Creasy M, Elliott M et al: Maternal factors associated with fetal chromosomal anomalies in spontaneous abortions. J Obstet Gynecol 83:621, 1976 |
187 | Dolan-Mullen P, Ramierez G, Groff JY: A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol 171:1328, 1994 |
188 | Martin TR, Bracken MB: Association of low birth weight with passive smoke exposure in pregnancy. Am J Epidemiol 124:633, 1986 |
189 | Marcus BH, Albrecht AE, King TK et al: The efficacy of exercise as an aid for smoking cessation in women. Arch Intern Med 159:1229, 1999 |
190 | Tonnesen P, Norregaard J, Simonsen K et al: A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325:311, 1991 |
191 | Ogburn PL, Hurt RD, Croghan IT et al: Nicotine patch use in pregnant smokers: Nicotine and cotinine levels and fetal effects. Am J Obstet Gynecol 181:736, 1999 |
192 | Jones KL, Smith DW, Ulleland CN et al: Patterns of malformation in offspring of chronic alcoholic mothers. Lancet 1:1267, 1973 |
193 | Rosett HL: A clinical perspective of the fetal alcohol syndrome. Alcohol Clin Exp Res 4:119, 1980 |
194 | Jones KL, Smith DW, Streissguth AP et al: Outcome of offspring of chronic alcoholic women. Lancet 1:1076, 1974 |
195 | Ouellette EM, Rosett HL, Rosman NP et al: Adverse effects on offspring of maternal alcohol abuse during pregnancy. N Engl J Med 297:528, 1977 |
196 | Mills JL, Graubard BI: Is moderate drinking during pregnancy associated with an increased risk of malformations. Pediatrics 80:309, 1987 |
197 | Sokol RJ, Martier SS, Ager JW: The T-ACE questions: Practical prenatal detection of risk-drinking. Am J Obstet Gynecol 160:863, 1989 |
198 | Van den Berg BJ: Epidemiologic observations of prematurity: Effects of tobacco, coffee and alcohol. In: Reed DM, Stanley FJ (eds): The Epidemiology of Prematurity. Baltimore, Urban & Schwarzenberg, 1977 |
199 | Linn S, Schoenbaum SC, Monson RR et al: No association between coffee consumption and adverse outcomes of pregnancy. N Engl J Med 306:141, 1982 |
200 | Martin TR, Bracken MB: The association between low birth weight and caffeine consumption during pregnancy. Am J Epidemiol 126:813, 1987 |
201 | Beaulac-Baillargeon L, Desrosiers C: Caffeine-cigarette interaction on fetal growth. Am J Obstet Gynecol 157:1236, 1987 |
202 | Munoz LM, Lonnerdal B, Keen CL et al: Coffee consumption as a factor in iron deficiency anemia among pregnant women and their infants in Costa Rica. Am J Clin Nutr 48:645, 1988 |
203 | Infante-Rivard C, Fernandez A, Gauthier R et al: Fetal loss associated with caffeine intake before and during pregnancy. JAMA 270:2940, 1993 |
204 | Mills JL, Holmes LB, Aarons JH et al: Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation. JAMA 269:593, 1993 |
205 | Klebanoff MA, Levine RJ, DerSimonian R et al: Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 341:1639, 1999 |
206 | Sturtevant FM: Use of aspartame in pregnancy. Int J Fertil 30:85, 1985 |
207 | Finnegan LP, Wapner RJ: Narcotic addiction in pregnancy. In: Niebyl JR (ed): Drug Use in Pregnancy. Philadelphia, Lea & Febiger, p 203, 1988 |
208 | Greenland S, Staisch KJ, Brown N et al: The effects of marijuana use during pregnancy: Part I. A preliminary epidemiologic study Am J Obstet Gynecol 143:408, 1982 |
209 | Fried PA, Buckingham M, Von Kulmiz P: Marijuana use during pregnancy and perinatal risk factors. Am J Obstet Gynecol 146:992, 1983 |
210 | Zuckerman B, Frank DA, Hingson R et al: Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320:762, 1989 |
211 | Acker D, Sachs BP, Tracey KJ et al: Abruptio placentae associated with cocaine use. Am J Obstet Gynecol 146:220, 1983 |
212 | Little BB, Snell LM, Klein VR et al: Cocaine abuse during pregnancy: Maternal and fetal implications. Obstet Gynecol 73:157, 1989 |
213 | Bingol N, Fuchs M, Diaz V et al: Teratogenicity of cocaine in humans. J Pediatr 110:93, 1987 |
214 | MacGregor SN, Keith LG, Chasnoff IJ et al: Cocaine use during pregnancy: Adverse perinatal outcome. Am J Obstet Gynecol 157:686, 1987 |
215 | Keith LG, MacGregor S, Friedell S et al: Substance abuse in pregnant women: Recent experience at the perinatal center for chemical dependence of Northwestern Memorial Hospital. Obstet Gynecol 73:715, 1989 |
216 | Chasnoff IJ, Griffith DR, MacGregor S et al: Temporal patterns of cocaine use in pregnancy. JAMA 261:1741, 1989 |
217 | Volpe JJ: Effect of cocaine use on the fetus. N Engl J Med 327:399, 1992 |
218 | Handler A, Kistin N, Davis F et al: Cocaine use during pregnancy: Perinatal outcomes. Am J Epidemiol 133:818, 1991 |
219 | Little BB, Snell LM: Brain growth among fetuses exposed to cocaine in utero Asymmetrical growth retardation. Obstet Gynecol 77:361, 1991 |
220 | Chasnoff IJ, Chisum GM, Kaplan WE: Maternal cocaine use and genitourinary tract malformations. Teratology 37:201, 1988 |